Definitive Healthcare Corp (DH)vsEli Lilly and Company (LLY)
DH
Definitive Healthcare Corp
$0.76
-1.14%
HEALTHCARE · Cap: $85.30M
LLY
Eli Lilly and Company
$1,117.26
+0.92%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 30224% more annual revenue ($72.25B vs $238.26M). LLY leads profitability with a 35.0% profit margin vs -71.5%. LLY earns a higher WallStSmart Score of 76/100 (B+).
DH
Hold37
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.5%
Fair Value
$7.87
Current Price
$0.76
$7.11 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -116.5% — below average capital efficiency
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DH
The strongest argument for DH centers on Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : DH
The primary concerns for DH are EPS Growth, Market Cap, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
DH profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
DH carries more volatility with a beta of 1.33 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 37/100), backed by strong 35.0% margins and 55.5% revenue growth. DH offers better value entry with a 78.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Definitive Healthcare Corp
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Definitive Healthcare Corp (DH) is a premier provider of comprehensive data and analytics solutions tailored for the healthcare sector, serving a broad spectrum of clients, including pharmaceutical firms, payers, and healthcare providers. The company leverages vast datasets and advanced real-time analytics to drive operational efficiency and provide strategic insights, ultimately enhancing patient outcomes. Positioned at the forefront of a rapidly evolving healthcare landscape, Definitive Healthcare is dedicated to delivering innovative, data-centric solutions that not only optimize operational performance but also confer competitive advantages to its partners. As demand for sophisticated healthcare analytics surges, DH is poised to be an influential player in redefining healthcare delivery.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?